Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Rui Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, State Key Laboratory of Vascular Homeostasis …. Hauptthemen laut MEDLINE: Neoplasms, Proteolysis, Nanotechnology, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Proteolysis-targeting chimeras (PROTACs) have emerged as a breakthrough therapeutic strategy in oncology, enabling the selective degradation of traditionally "undruggable" proteins via the ubiquitin-proteasome system. However, their clinical translation remains challenging due to high molecular weight, limited aqueous solubility, and metabolic instability, which limit systemic bioavailability and tumor penetration. To address these challenges, a variety of nanocarrier systems have been developed to improve the stability, pharmacokinetics, and tumor-specific accumulation of PROTACs. Beyond delivery enhancement, nanotechnology also enables the creation of next-generation PROTAC modalities, such as mRNA-encoded and RNA-scaffolded PROTACs, thereby expanding their therapeutic potential. In parallel, stimuli-responsive nanocarriers offer spatiotemporal control over PROTAC release, maximizing therapeutic efficacy while minimizing off-target effects. This review provides a comprehensive overview of nanotechnology-enabled strategies for PROTAC delivery, highlights key translational challenges, and discusses future directions to facilitate their clinical advancement in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, College of Future Technology, National Biomedical Imaging Center, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100871, China.
- School of Light Industry Science and Engineer, Beijing Technology and Business University, Beijing 100048, China.
ORCID-Profile: Rui Li, Renfa Liu, Zhifei Dai
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Li, R., Zhang, S., Xu, Y., Liu, R., & Dai, Z. (2025). Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00305
Vancouver
Li R, Zhang S, Xu Y, Liu R, Dai Z. Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00305
BibTeX
@article{Li2025,
author = {Li, Rui and Zhang, Shuhao and Xu, Yunxue and Liu, Renfa and Dai, Zhifei},
title = {Nanoenabled Strategies Enhancing PROTACs for Cancer Therapy},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00305}
}
EUVIMED